improve disease-free survival in higher risk patients [1] . Remnant ablation requires elevated thyroidstimulating hormone (TSH) levels which increase radioiodine uptake by residual tissue and facilitate an effective ablation. TSH elevation can be achieved by discontinuation of thyroxine therapy (thyroid hormone withdrawal, THW) for at least 4-5 weeks or by administration of recombinant human TSH (rhTSH -Thyrogen ® ). The use of Thyrogen ® allows the patient to continue T4 therapy, thus avoiding the consequence of iatrogenic hypothyroidism [2] . The benefits associated with the use of Thyrogen ® include avoidance of the symptoms of hypothyroidism, which include fatigue, weakness, constipation, depression, impaired memory and bodily pain. Recently, hypothyroidism has been associated with cognitive and motor impairments that are likely to constitute hazards in the operation of motor vehicles and a public safety risk [3] . Avoidance of hypothyroidism via Thyrogen ® therapy has been found to be associated with consequent better health-related quality of life, little or no productivity loss and a reduction in the need for GP visits or medications [4] . In addition, use of Thyrogen ® has been shown to allow a shorter duration of the preablative period and a faster radioiodine clearance rate [5, 6] with the possibility of less radiation exposure to non-targeted organs and earlier discharge from radioprotective wards [7, 8] .
More importantly, such benefits are achieved with ablation efficacy comparable with thyroid hormone withdrawal. This was initially demonstrated in an international randomized controlled study showing similar success rates in exogenous-and endogenousstimulated patients [5] . Furthermore, two phase III studies (HiLo [9] and ESTIMABL [2] ) have independently confirmed similar efficacy for the two methods of TSH stimulation across two 131I activity levels (30 or 100 mCi). A meta-analysis performed in 2014 that included 7 randomized controlled trials (RCTs) with a total of 1535 patients came to the same conclusion [10] . In 2012, the use of Thyrogen ® has been approved for an 131I dose range of 30-100 mCi for postoperative remnant ablation, instead of the previous approval of just 100 mCi 131I [11] . Due to this change, a pre-existing economic model [12, 13] was adapted to compare exogenous TSH therapy (Thyrogen   ®   ) with thyroid hormone withdrawal in the Italian setting. Unlike all previous adaptations, including the most recent one in the Korean setting [14] , our analysis takes into account both high-(100 mCi) and low-activities (30 mCi) of radioiodine. The aim of this study was to compare the estimated health benefits, cost and cost-effectiveness of TSH stimulation with and without Thyrogen ® in the Italian setting.
Methods
An Italian cost utility analysis was undertaken to assess the impact of exogenous vs. endogenous TSH stimulation before radioiodine remnant ablation of patients with thyroid cancer who have undergone total or near-total thyroidectomy. Consistent with the patient characteristics of the three pivotal trials [2, 5, 9] patients with aggressive types of thyroid cancer or distant metastasis were not included in the model. The local healthcare payer perspective was adopted in the base case scenario. Nevertheless, the impact of indirect costs (only appreciable within the societal perspective) is explored in a sensitivity analysis. In order to capture the differential costs and utilities associated with the short-term morbidity caused by induced hypothyroidism the economic model has a 17-week time horizon, assuming no differences beyond that point, as described elsewhere [13] .
Model structure
The structure of the Markov model ( Figure  1) is based upon the model originally developed by Mernagh et al. [13] . Briefly, treatment costs and health outcomes associated with exogenous stimulation and endogenous stimulation were computed in four distinct health states: pre-ablation (time between thyroidectomy and ablation), ablation, postablation (divided into two 4-week periods: initial and second post-ablation period), and well/recovery. Furthermore, in order to incorporate the extended indication of Thyrogen ® for the use with a range of 30-100 mCi of radioiodine, treatment is stratified by patients who receive high-and low-activity in the ablation state. The cycle length of the model is one week. Costs and quality adjusted life years (QALY) specific to each health state were estimated, summarized and converted into a corresponding incremental cost-effectiveness ratio (ICER).
Clinical inputs
Local data provided from Italian clinicians via a survey of treatment practice (reported in Appendix A), were used to tailor the analysis to the Italian setting. Based on treatment survey responses, ≈40% of patients receive 30 mCi and ≈60% patients receive 100 mCi radioiodine. Consistent with previous economic evaluations [12, 13] , and according to the available body of clinical evidence the model assumed successful ablation in all the patients regardless of the method of preparation and administered radioiodine activity [2, 5, 9, 10] .
Length of time between thyroidectomy and radioiodine ablation
Since endogenously-stimulated patients can undergo ablation only after TSH levels have naturally elevated to a suitable level, the interval between thyroidectomy and ablation might vary from patient to patient. This will be further addressed in the discussion since it might impact the ward organization. In our base case, following recovery from total thyroidectomy (inclusive of histology results), the pre-ablation period (time between the decision to perform ablation and the ablation procedure) is about 4 weeks. This interval was calculated based on the answers provided by the centers involved in the survey and reflects our experience as well as real life medical practice. In contrast, exogenouslystimulated patients can experience a much shorter pre-ablation preparation period. A summary of the duration of each health state and the transition probabilities allowing patients to move from pre-ablation to ablation is shown in Appendix B.
Length of stay in radioprotective ward
Consistent with the results of the local treatment survey, the average length of stay used in the model was distinguished by the radioiodine activity, 2.6 and 3.0 days for 30 mCi and 100 mCi activities, respectively. The length of stay for exogenously and endogenously-stimulated patients, in absence of local data, were assumed to be the same. This assumption is conservative (thus penalizing Thyrogen ® ) since there is a solid body of evidence linking Thyrogen ® to a faster clearance of 131I after radioiodine ablation [6, 15, 16] , leading to a shorter stay in the radioprotective ward [7, 8, 17] . Differences in the length of stay, using literature data, were tested in the sensitivity analysis. The impact of length of stay on modeled outcomes is addressed in the discussion.
Utility weights
The time spent in each state was quality adjusted using utility weights. Utility weights for the pre-ablation and the initial post-ablation periods were derived from the SF-36 data collected during the initial pivotal RCT [5] and transformed into utility weights using the SF-6D method [18] . The mean disutility associated with thyroid hormone therapy withdrawal in the endogenously-stimulated arm compared to the exogenously-stimulated arm is a direct and expected consequence of the symptoms associated with hypothyroidism [5, 19] . In order to reflect the disutility that patients may feel as a consequence of the ablation procedure and the associated time spent in the hospital, the ablation utility weights were based on those of pre-ablation, with an assumed extra disutility of 0.1 applied in each arm. The post-ablation period is divided into two sequential 4-week periods: in order to capture a gradual recovery, leading to the well health state, the initial period has a lower uti- 
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lity than the second. In particular, the utility for 0-4 weeks post-ablation was derived directly from 1-month post-ablation SF-36 data from pivotal trial, whereas the utility for 4-8 weeks post-ablation period was an average of the utility weights of the well and initial postablation period [5] . Finally, a conventional value of 1 was attributed to the well utility as representative of perfect health. As this may not be true for all the patients a lower value was tested in a sensitivity analysis. A summary of clinical input and utility weights used in the model are reported in Table I .
resource use and cost input
Unit costs applied to resource use are taken from the Tariff System of Lombardy [21] , drug costs were derived from Codifa [22] . In the exogenously-stimulated arm the net acquisition cost of Thyrogen ® plus administration was taken into account (a visit for each of the 2 injections). According to survey responses, an initial TSH quantification test would be performed 4 weeks after T4 withdrawal, in the case of endogenous stimulation. If the TSH level had not reached suitable levels, ablation would be postponed by approximately one week. The survey also reveals that on average 2.42% and 38.25% of endogenously-stimulated patients would seek additional treatment from a GP or specialist, respectively, looking for relief of symptoms related to iatrogenic hypothyroidism. Finally, the proportion of radioiodine ablation patients taking T3 (liothyronine sodium) during the period between their thyroidectomy and radioiodine ablation is also based on data from the treatment survey. Unit costs incorporated into the economic model and source, and total costs per health state in each arm are presented in Table II and Table  III , respectively.
Sensitivity analysis
Individual one-way deterministic sensitivity analyses were performed to test the impact of key assumptions, and to better understand the main drivers of the economic analysis. In particular, we tested the impact of: -Including indirect costs, thus adopting a societal perspective. This was done according to the friction cost methodology:
where P is the daily productivity loss, ω is the daily wage (calculated from total average weekly earnings divided by seven days) and δ is equal to the unemployment-adjusted labor force participation rate. As both ω and δ are likely to change substantially from one economy to another, the daily productivity loss is a sensitive variable. results
Base case
The results presented in Table IV illustrate the cost of treatment with Thyrogen ® in the Italian setting when compared with endogenous stimulation of TSH before ablation. The incremental cost-effectiveness ratio is € 18,357.18 per each QALY gained, meaning that Thyrogen ® represents a cost-effective solution.
Sensitivity analysis
The sensitivity analysis identified as the most critical variable the potential reduction in length of stay in the radioprotective ward ( Figure II) . When a 1 day difference was assumed for both high-and low-activity radioiodine, Thyrogen ® dominates endogenous stimulation as it still produced greater health gains whilst costing less. In parallel, if it is assumed that this difference is seen only for the percentage of patients receiving high activity 131I, consistent with Mallick et al. results [9] , we calculated an incremental cost-effectiveness ratio of € We further combined the effect of these assumptions in a multivariate sensitivity analysis (Table V) . In particular, the first analysis shows the impact of reducing the utility score in the well health state as well as reducing the utility difference in the preablation health state by 50%. The QALY gain shifts from 0.038 to 0.028 and the ICER increased to € 24,372.27 per QALY. The cost of hospitalization had no impact in the base case analysis because we assumed that the length of stay was only dependent on the activity of radioiodine received. The daily cost of hospitalization was therefore tested using length of stay estimates from Borget et al. [7] at the dIscussIon Thyrogen ® avoids daily life disruptions and preserves patients' QoL, whereas thyroid hormone withdrawal (THW) has been shown to produce a QoL deterioration greater than that of heart failure, depression and migraine headache [19, 27] . The patients' perspective on the desirability of these two alternatives is evidenced by the finding that between 86% and 97% of interviewed patients favored rhTSH over THW [28, 29] . As indicated by our analysis, the use of Thyrogen ® is cost-effective according to the Italian conventional willingness to pay (WTP) thresholds (25,000-40,000 €/QALY) [26] . To our knowledge this is the first study assessing cost-effectiveness of Thyrogen ® in the Italian setting in patients who receive either high-(100 mCi) or lowactivity (30 mCi) radioiodine for remnant ablation post-thyroidectomy. A number of cost-effectiveness analyses of Thyrogen ® have been conducted previously, however it is well known that results cannot be transferred directly across different countries [30] . Our findings are consistent with three cost-utility analyses conducted using the same model in the German, Canadian and Korean settings in which ICERs were equal to 958 €/QALY, 1,520 Canadian $/QALY and 26,697,361 W/QALY, respectively [12] [13] [14] . Most recently, a cost-effectiveness analysis performed in France alongside the ESTIMA-BL trial adopted a longer time horizon and considered the consecutive use of Thyrogen ® in both ablation and follow up procedures [31] . Results cannot be directly compared for a number of reasons. First, clinical pathways, clinicians' attitudes and/or reimbursement mechanism in France might be different from Italy and might imply differences in term of time and costs. Secondly, as a consequence of the longer time horizon adopted in the French study (8 +/-2 months vs 17 weeks), the QoL estimates, including both physical and mental components, should be compared only in the initial 3 months, which are common to both simulations. Within such period the QoL scores are quite comparable, however, after this point, in the French study there appears to be some sort of a prolonged "rebound effect" in the THW cohort. Authors did not comment on the length and extent of this phenomenon. In addition, neither the hospital length of stay (2.6 vs 2.8 days) nor the sick leave time (23 vs. 24 days) appeared to be significantly different, in contrast to other retrospective reports [7, 8] . We remind that length of stay is mainly driven by how each nuclear medicine ward is organized (number of beds, use of beds -7/7 or just Monday to Fridaypresence/absence of waiting lists) and, above all, by the remuneration system. Culturally in Italy there is the common misconception that identifies remuneration tariffs such as Disease Related Groups (DRGs) with real costs. Additionally, the DRG applied for ablation is calculated on a minimum length of stay of two nights, so any earlier discharge, even if feasible and desirable, might be internally perceived as a productivity loss instead of a competitive advantage. The aim of our research is twofold: on the one hand, to support informed decisions with the most conservative modelling approach (even though less favorable to Thyrogen ® ), and on the other hand, to stimulate constructive debate. Therefore, we decided to run the base case scenario under the most conservative assumptions, assuming no difference in length of stay. However, in the sensitivity analysis we relaxed our hypothesis and assumed an earlier discharge for Thyrogen ® treated patients (Borget reported a reduction from 3.5 to 2.4 days in 2008 [7] , whereas Vallejo-Casas in 2011 documented 1.41 vs. 2.02 days [8] ); in this scenario, Thyrogen ® dominates endogenous stimulation by providing better QoL outcomes along with cost savings. In a strict analogy and despite their paramount importance, we excluded societal benefits such as productivity gains in the base case analysis. This might be counterintuitive given the considerable body of evidence suggesting that endogenous stimulation results in greater work absenteeism [4, 28, 32, 33] . Albeit not in ablation but in the follow up, Dietlein et al. [28] reported workday loss in 70% of THW patients in follow-up (40% with Thyrogen ® ); Luster et al. [4] , back in 2005, reported a similar figure (65%). In both studies the average workday loss was between 11 and 12 days (vs. 3 to 4 days in case of Thyrogen ® use). Borget et al. [32] documented a 8.1 days difference in 2007 whereas the ESTIMABL study [31] reported no difference. We speculate that sick leave duration is highly dependent of the clinical practice: in some cases is set on the basis of the disease (thyroid cancer) and not on the basis of the treatment. In other words, the use of a standard protocol, possibly defined on general DTC patients characteristics such as age, sex, comorbidities, would totally prevent to appreciate the maintenance of a state of wellbeing that is compatible with normal productivity in most patients. With the inclusion of such indirect costs, the cost-effectiveness of Thyrogen ® would further improve to 14,695.67 €/QALY when compared with endogenous stimulation. 
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There are some additional potential Thyrogen ® advantages that we were not able to address in our analysis. The intensity of individual symptoms of iatrogenic hypothyroidism may vary from patient to patient; however, the cognitive, motor and psychological deficitslinked to severe hypothyroidism and resulting in the impaired ability to operate machinery or drive vehicles -might have been underestimated. Driving motor vehicles such as cars or motorbikes, should be avoided in the severe hypothyroid state because of decreased finemotor performance and processing speed, and slowed reaction times (braking times were increased by 8.0%, equivalent to the motor slowing caused by alcohol ingestion at a blood concentration of 0.082 g/100 ml; this concentration is above the levels allowed within EU for driving) [3] . This is quite relevant since driving habits appear to be difficult to change in at least 30% of THW cases, irrespectively of a strong negative medical advice [4] . The use of Thyrogen ® may also improve overall ward efficiency, lowering fixed costs and halve waiting lists, in analogy of what measured in other countries [8, 24] . Little is known about the real organizational aspects related to ablation and isolation rooms in Italian hospitals, as a consequence of the shorter length of stay and the more exact scheduling of admissions and discharges.
In conclusion, Thyrogen ® represents a good treatment option for patients as well as a difficult exercise for any healthcare professional operating in a scenario with limited resources: by training, physicians have to keep patients from harm, and this should strongly advise against inducing hypothyroidism, even if temporary, when an alternative, such as Thyrogen ® , is available. We strongly advocate for future studies about broader aspects related to hypothyroidism, since this would allow more informed decision making. Retrospective analysis on administrative claim databases as well as specific patient interviews might shed some light whether the use of Thyrogen ® is able to improve patient safety by reducing accidents, either at home or related to driving, as well as unscheduled use of healthcare resources in the emergency departments.
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references AppendIx A
The survey (Table IA) was conducted amongst clinical experts in endocrinology, nuclear medicine and surgery, currently practicing in Italy. The objective of the survey was to establish the current practice of radioiodine ablation (both high and low-dose) for well differentiated thyroid cancer in those patients who are endogenously-stimulated prior to ablation. Practice nurse alone 56%
GP Alone 0%
Specialist alone 11%
Practice nurse and specialist 33%
Practice nurse and GP 0% 
